Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.76 Insider Own0.56% Shs Outstand79.94M Perf Week16.30%
Market Cap66.35M Forward P/E- EPS next Y-0.23 Insider Trans0.00% Shs Float79.50M Perf Month34.70%
Income-49.15M PEG- EPS next Q-0.07 Inst Own1.77% Short Float0.41% Perf Quarter29.67%
Sales11.65M P/S5.70 EPS this Y72.08% Inst Trans142.51% Short Ratio0.93 Perf Half Y-38.52%
Book/sh0.18 P/B4.60 EPS next Y10.00% ROA-81.75% Short Interest0.32M Perf Year-48.77%
Cash/sh0.35 P/C2.36 EPS next 5Y- ROE-188.40% 52W Range0.51 - 2.53 Perf YTD-47.13%
Dividend Est.- P/FCF- EPS past 5Y21.53% ROI-242.98% 52W High-67.19% Beta1.53
Dividend TTM- Quick Ratio1.05 Sales past 5Y0.00% Gross Margin52.24% 52W Low62.75% ATR (14)0.07
Dividend Ex-Date- Current Ratio1.14 EPS Y/Y TTM-30.06% Oper. Margin-334.25% RSI (14)68.03 Volatility11.80% 9.57%
Employees38 Debt/Eq0.87 Sales Y/Y TTM- Profit Margin-421.69% Recom1.00 Target Price13.75
Option/ShortYes / Yes LT Debt/Eq0.55 EPS Q/Q95.14% Payout- Rel Volume0.77 Prev Close0.79
Sales Surprise1929.41% EPS Surprise100.00% Sales Q/Q- EarningsMay 28 BMO Avg Volume347.26K Price0.83
SMA2031.70% SMA5026.94% SMA200-26.13% Trades Volume266,381 Change5.08%
Date Action Analyst Rating Change Price Target Change
May-18-17Upgrade Maxim Group Hold → Buy $1 → $3
Feb-13-17Initiated Rodman & Renshaw Buy $3
Aug-12-16Downgrade Maxim Group Buy → Hold $4 → $1
Aug-17-15Reiterated Maxim Group Buy $8 → $4
Jul-27-15Reiterated ROTH Capital Buy $10.50 → $7
Jun-22-15Initiated JMP Securities Mkt Outperform $5
Jun-18-24 07:37AM
Jun-05-24 03:17PM
May-30-24 07:00AM
May-29-24 08:03AM
May-28-24 11:53AM
07:00AM Loading…
May-24-24 07:00AM
May-22-24 07:00AM
May-17-24 05:00PM
May-06-24 07:00AM
Apr-17-24 07:00AM
Apr-10-24 07:00AM
Apr-01-24 09:00AM
Mar-27-24 12:23PM
Mar-26-24 07:00AM
07:00AM Loading…
Mar-20-24 07:00AM
Mar-06-24 08:00AM
Mar-04-24 07:00AM
Feb-28-24 07:00AM
Feb-25-24 02:12PM
Feb-16-24 07:00AM
Dec-21-23 07:00AM
Nov-21-23 03:45PM
Nov-20-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 03:12PM
Oct-31-23 09:00AM
Oct-30-23 11:38AM
Oct-12-23 07:00AM
Sep-28-23 07:00AM
07:00AM Loading…
Sep-19-23 07:00AM
Sep-14-23 05:36AM
Sep-11-23 07:00AM
Sep-05-23 06:04AM
Aug-31-23 08:18AM
Aug-30-23 07:00AM
Aug-22-23 07:00AM
Aug-07-23 02:34PM
Jul-18-23 03:22PM
Jul-17-23 07:00AM
Jun-29-23 02:00PM
Jun-07-23 05:25AM
May-24-23 07:00AM
May-17-23 07:00AM
May-04-23 01:56PM
Apr-25-23 07:00AM
Apr-17-23 11:00AM
Apr-04-23 08:21PM
Mar-24-23 07:15AM
Mar-23-23 11:42AM
Mar-22-23 07:00AM
Mar-15-23 07:00AM
Mar-06-23 07:00AM
Jan-04-23 07:00AM
Dec-20-22 12:36PM
Dec-05-22 04:00AM
Nov-28-22 04:30PM
Nov-15-22 07:00AM
Nov-10-22 04:30PM
Nov-04-22 04:30PM
Nov-03-22 09:11AM
Nov-02-22 09:21AM
Sep-27-22 07:00AM
Sep-19-22 08:00AM
Sep-15-22 12:38PM
Sep-12-22 07:00AM
Aug-18-22 07:47AM
Aug-16-22 07:00AM
Aug-11-22 07:00AM
Jun-29-22 08:00AM
Jun-28-22 07:00AM
Jun-16-22 07:00AM
May-12-22 10:16AM
May-11-22 07:00AM
May-05-22 07:00AM
Mar-17-22 08:55AM
Mar-16-22 07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Jan-31-22 04:20AM
Jan-24-22 07:00AM
Jan-18-22 07:00AM
Dec-17-21 07:00AM
Dec-15-21 07:00AM
Nov-18-21 07:00AM
Nov-12-21 07:16AM
Nov-04-21 09:15AM
Oct-13-21 08:30AM
Oct-06-21 04:38AM
Aug-18-21 07:00AM
Aug-12-21 09:30AM
Jun-30-21 08:58AM
Jun-04-21 09:04AM
May-26-21 07:00AM
May-20-21 07:00AM
May-04-21 08:56AM
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.